Loading asset research
EyePoint Inc. Common Stock
EYPTNasdaq · USD · StocksQuote as of · Exchange session not verified$4.23
-0.47%
Today
EYPT
Loading 1D prices…
Market cap
$354.6M
Volume
2.7M
52w high
$19.1152w low
$3.95Company profile
EyePoint Inc. Common Stock
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Sector
Industrials
Industry
Laboratory Analytical Instruments
Exchange
Nasdaq
Display currency
USD
Location
Watertown, MA, United States
Employees
214
Fiscal year end
1231
CIK
1314102
Session & valuation
Open$4.32
Previous close$4.25
Day high$4.43
Day low$4.17
30-day avg. volume5.5M
Outstanding shares86.2M
Diluted EPS-$3.17
Latest annual period
P/E (trailing)-1.33
P/E (forward)-1.53
Price / book10.68
Beta1.64
Dividend yield—
Deterministic peer set
Companies with SEC SIC 3826
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MASS908 Devices Inc. Common Stock | $393.5M | $56.2M | +34.68% | $0.54 | +1.82% | Buy |
| PACBPacific Biosciences of California Inc. Common Stock | $404.1M | $160M | -341.49% | -$1.82 | +2.36% | Hold |
| CTKBCytek Biosciences Inc. Common Stock | $599.2M | $201.5M | -33.02% | -$0.52 | +1.55% | Buy |
| NAUTNautilus Biotechnology Inc. Common Stock | $129.8M | $0.00 | — | -$0.47 | +2.53% | Buy |
| QTRXQuanterix Corporation Common Stock | $121.1M | $138.9M | -77.18% | -$2.51 | +2.20% | Hold |